Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)

Trial Profile

Open Label Extension Study to ZYN2-CL-03 to Assess the Long Term Safety and Efficacy of ZYN002 Administered as a Transdermal Gel to Patients with Partial Onset Seizures (STAR 2)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Acronyms STAR2
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 25 Apr 2018 Results presented in a Zynerba Pharmaceuticals media release.
    • 25 Apr 2018 According to the Zynerba Pharmaceuticals media release, 12 months results from STAR 2 study were presented at the 2018 Annual Meeting of the American Academy of Neurology (AAN).
    • 17 Apr 2018 Planned End Date changed from 14 Dec 2018 to 14 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top